An adoption timeline was constructed.Sixty-nine payers had a sequencing policy. Chemotherapy Decisions and Patient Experience With the Recurrence Score Assay for Early-Stage Breast Cancer. Monoclonal On multivariable analysis, nipple-sparing mastectomy was associated with a lower risk of breast cancer-specific mortality compared to non-nipple-sparing mastectomy [hazard ratio (HR) 0.71, 95% confidence interval (CI) 0.51-0.98]. Imaging revealed multiple bilateral breast masses and right axillary adenopathy, and core needle biopsies showed invasive ductal carcinoma in both the right and left breast. Among ovarian cancer patients, cancer-specific mortality was lower with PVs in BRCA2 (HR=0.35, 95% CI=0.25-0.49) and genes other than BRCA1/2 (HR=0.47, 95% CI=0.32-0.69). Knowledge of the potential for breast MRI enhancement subsequent to DL, which can mimic the appearance of a pathologic lesion, is critical to the care of patients who undergo breast MRI and DL or other intraductal cannulation procedures. Clinician assessment and communication regarding financial toxicity must improve; cure at the cost of financial ruin is unacceptable. Schapira, L., Hofmeister, E., Kurian, A. W., Zion, S., Shen, H., Torres, T., Berek, J. S., Palesh, O. Kurian senior was a chemical engineer and the general manager of Graphite India. Results were similar for breast cancer-specific survival, except that African Americans and non-Hispanic Whites living in high-SES neighborhoods had similar survival.Strategies to address the underlying factors that may influence treatment intensity and adherence, such as comorbidities and logistical barriers, should be targeted at low-SES non-Hispanic White and all African American patients. For women whose first breast tumors were HR negative, the risk of a contralateral primary tumor was statistically significantly higher than that for women whose first tumors were HR positive (SIR = 3.57, 95% CI = 3.38 to 3.78, AR = 18 per 10 000 PY), and it was associated with a much greater likelihood of an HR-negative second tumor (SIR for HR-positive second tumors = 1.94, 95% CI = 1.77 to 2.13, AR = 20 per 10 000 PY; SIR for HR-negative second tumors = 9.81, 95% CI = 9.00 to 10.7, AR = 24 per 10 000 PY). Nevertheless, breast cancer mortality rates will be higher for women with higher PRS313 as increasing PRS313 is associated with an increased risk of disease. Sixty percent (n=187) reported feeling very or extremely concerned that the pandemic would affect their cancer and disproportionately experienced among those with advanced cancer stages compared with earlier stages (P<0.001). We evaluated joint associations of race/ethnicity, healthcare, sociodemographic, and lifestyle factors with mortality.Among women with ER/PR+ BC, BC-specific mortality was similar among Hispanic and Asian American women, but higher among African American women (hazard ratio (HR) 1.31, 95% confidence interval 1.05-1.63) compared to non-Hispanic White (NHW) women. paclitaxel to see how well they work with or without bevacizumab in treating patients with We considered whether weight is more informative than body mass index = weight/height2 (BMI) when predicting breast cancer risk for post-menopausal women, and if the weight association differs by underlying familial risk. We found substantially higher hazards of breast cancer death among African-American women with Stage II/III HR+/HER2- (HR, 1.31, 95% CI, 1.03-1.65, and HR, 1.39, 95% CI, 1.10-1.75, respectively) and Stage III triple-negative cancers relative to whites.There are substantial racial/ethnic disparities among patients with Stages II/III HR+/HER2- and Stage III triple-negative breast cancers but not for other subtype and stage.These data provide insights to assess barriers to targeted treatment (e.g. Two-fold increased risks were associated with migration at age 40 years and longer U.S. residence (30 years or 75% of life). This multi-institutional, multidisciplinary approach may be useful for organizations to frame responses as similar legislation is passed across the United States. [15], As the President of Product Development, he oversaw Oracle's 3,000-odd product development efforts. The primary outcome for this study is the type and timing of risk management options (surveillance, chemoprevention, surgery) taken up over the course of the study (i.e., 12 months). Breast cancer remains the most common female malignancy in the United States. We examined oncologists' influence on use of recurrence score (RS) testing and chemotherapy in the community.We identified 7810 women with stages 0-II breast cancer treated in 2013-15 through the SEER registries of Georgia and Los Angeles County. These PRSs were evaluated in 89,898 women from 3 prospective studies (1592 incident cases).The best performing PRS (genome-wide set of single-nucleotide variations [formerly single-nucleotide polymorphism]) had a hazard ratio per unit SD of 1.62 (95% CI= 1.46-1.80) and an area under the receiver operating curve of 0.635 (95% CI= 0.622-0.649). View details for DOI 10.1158/1055-9965.EPI-15-0055, View details for DOI 10.1001/jama.2015.8088. Temporal analyses revealed important trends: the possible contribution of the CMS NCD to a faster pace of coverage adoption, the interdependence in coverage timing among BlueCross BlueShield members, the impact of using a third-party policy on coverage timing, and the importance of small payers in early adoption. Thomas Kurian current age is 49 and comes fromPampady village of Kottayam district. B., Lee, R., Chan, S., Donlon, S. S., Ridge, Y., Panabaker, K., West, D. W., Whittemore, A. S., Ford, J. M. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. In particular, issues of risk associated with dense breast tissue, masking of cancers by dense tissue on mammograms, and the efficacy, benefits, and harms of supplementary screening tests were studied and consensus reached. Why did Google Cloud CEO Diane Greene Quit? While incidence rates of breast cancer molecular subtypes are well documented, effects of molecular subtypes on breast cancer-specific survival using largest population coverage to date are unknown in the U.S.Using SEER (Surveillance, Epidemiology and End Results) cancer registry data, we assessed survival after breast cancer diagnosis among women diagnosed during 2010-2013 and followed through 12/31/2014. Methods:We investigated the association of specific comorbidities with mortality in a multiethnic cohort of 8,952 breast cancer cases within the California Breast Cancer Survivorship Consortium (CBCSC), which pooled questionnaire and cancer registry data from five California-based studies. View details for DOI 10.1200/JCO.2016.71.6480. Risk-reducing salpingo-oophorectomy has been shown to reduce ovarian cancer risk, but its association with breast cancer risk is less clear.To assess the association of RRSO with the risk of breast cancer in women with BRCA1 and BRCA2 pathogenic variants.This case series included families enrolled in the Breast Cancer Family Registry between 1996 and 2000 that carried an inherited pathogenic variant in BRCA1 (498 families) or BRCA2 (378 families). In the Oncoshare project, we have developed such methods as part of a collaborative multi-institutional CER study of patterns, predictors, and outcome of breast cancer care. Scott, D., Kingham, K., Hodan, R., Ma, C., Mills, M., Ford, J. M., Kurian, A. W., Telli, M. L. DO RESEARCH PARTICIPANTS DIFFER BY RECRUITMENT SOURCE?OBSERVATIONS FROM A STUDY OF NEWLY-DIAGNOSED BREAST CANCER PATIENTS. For more information, please contact Janet Pan, 650-723-0628. Also assessed was the association between second opinion and chemotherapy use, adjusting for chemotherapy indication and propensity for receiving a second opinion. Of the 63% associated with treatment, 31% (model range, 22%-37%) was associated with chemotherapy, 27% (model range, 18%-36%) with hormone therapy, and 4% (model range, 1%-6%) with trastuzumab. Kurian, A. W., Balise, R. R., McGuire, V., Whittemore, A. S. Predicting US breast cancer mortality rate in the year 2010, Plevritis, S. K., Sigal, B. M., Kurian, A. W., et al, Estimating the life years gained from breast MRI screening in women with BRCA1/2 mutations. Chris Mellor. The primary end point was pathologic complete response (no invasive carcinoma in breast or axilla). Variation in projected absolute lifetime risk of breast cancer associated with classical risk factors was greater for women with higher genetic risk (PRS313 and family history), and on average 17.5% higher in the highest vs lowest deciles of genetic risk. The authors described responses from approximately 73% of surgeons (370 surgeons), 61% of medical oncologists (306 medical oncologists), 67% of radiation oncologists (169 radiation oncologists), and 68% of patients (2502 patients).Approximately one-half (50.9%) of responding medical oncologists reported that someone in their practice often or always discusses financial burden with patients, as did 15.6% of surgeons and 43.2% of radiation oncologists. For more information, please contact Charlene Kranz, (650) 498 - 7977. Nevertheless, the unique associations seen for other modifiers support the conjecture that the histologic types of epithelial ovarian cancer have different etiologies, which should be addressed in future investigations of the molecular basis of ovarian cancers and their responses to therapies. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian focus specifically on the assessment of genetic mutations in BRCA1/BRCA2, TP53, and PTEN, and recommend approaches to genetic testing/counseling and management strategies in individuals with these mutations. All women were of European ancestry.For pregnanediol-3-glucuronide, there were no genome-wide significant associations; for oestrone-3-glucuronide, we identified a single peak mapping to the CYP3A locus, annotated by rs45446698. Results were robust to sensitivity analyses examining pleiotropy (including weighted-median-MR, MR-Egger).Our study provides strong evidence that greater overall physical activity, greater vigorous activity, and lower sedentary time are likely to reduce breast cancer risk. New technologies are being developed for early detection of multiple types of cancer simultaneously. in adult patients with triple negative breast cancer (estrogen receptor (ER)-negative, Daly, M. B., Pilarski, R., Berry, M., Buys, S. S., Farmer, M., Friedman, S., Garber, J. E., Kauff, N. D., Khan, S., Klein, C., Kohlmann, W., Kurian, A., Litton, J. K., Madlensky, L., Merajver, S. D., Offit, K., Pal, T., Reiser, G., Shannon, K. M., Swisher, E., Vinayak, S., Voian, N. C., Weitzel, J. N., Wick, M. J., Wiesner, G. L., Dwyer, M., Darlow, S. Reply to Comment on 'Statin use and all-cancer survival: prospective results from the Women's Health Initiative'. Pathogenic variants in PALB2 were associated with a moderate risk (odds ratio, 3.83; 95% CI, 2.68 to 5.63). The prognostic value was confirmed in another independent cohort (Gene Expression Omnibus GSE 1456), with log-rank P = .00058 for recurrence-free survival and log-rank P = .0026 for overall survival. Ho, W. K., Tan, M. M., Mavaddat, N. n., Tai, M. C., Mariapun, S. n., Li, J. n., Ho, P. J., Dennis, J. n., Tyrer, J. P., Bolla, M. K., Michailidou, K. n., Wang, Q. n., Kang, D. n., Choi, J. Y., Jamaris, S. n., Shu, X. O., Yoon, S. Y., Park, S. K., Kim, S. W., Shen, C. Y., Yu, J. C., Tan, E. Y., Chan, P. M., Muir, K. n., Lophatananon, A. n., Wu, A. H., Stram, D. O., Matsuo, K. n., Ito, H. n., Chan, C. W., Ngeow, J. n., Yong, W. S., Lim, S. H., Lim, G. H., Kwong, A. n., Chan, T. L., Tan, S. M., Seah, J. n., John, E. M., Kurian, A. W., Koh, W. P., Khor, C. C., Iwasaki, M. n., Yamaji, T. n., Tan, K. M., Tan, K. T., Spinelli, J. J., Aronson, K. J., Hasan, S. N., Rahmat, K. n., Vijayananthan, A. n., Sim, X. n., Pharoah, P. D., Zheng, W. n., Dunning, A. M., Simard, J. n., van Dam, R. M., Yip, C. H., Taib, N. A., Hartman, M. n., Easton, D. F., Teo, S. H., Antoniou, A. C. A case of a trans-masculine patient receiving testosterone with a history of estrogen receptor-positive breast cancer. View details for DOI 10.1007/s10549-022-06634-z, Human leukocyte antigen (HLA) genes play critical roles in immune surveillance, an important defence against tumors. Lung cancer survivors are at high risk of a second primary lung cancer (SPLC). View details for DOI 10.1200/JCO.22.01978. Both individual-level data as well as summary statistics for 164 single-nucleotide polymorphisms (SNPs) reported in genome-wide association studies of lifetime smoking index (LSI) or cigarette per day (CPD) were used to obtain MR effect estimates. View details for Web of Science ID 000329061100013, View details for PubMedCentralID PMC3864715. View details for DOI 10.1158/1055-9965.EPI-12-0149. He was an Arjay Miller Scholar. Stanford is currently not accepting patients for this trial. survival by adding iniparib (BSI-201/SAR240550) to the combination of gemcitabine/carboplatin Women with mutations in the BRCA1 or BRCA2 cancer susceptibility genes face unique choices regarding management of their high risk for breast and ovarian cancer that impact their reproductive options. Price, E. R., Hargreaves, J., Lipson, J. All odds ratios (ORs) were adjusted for age, country of origin, and calendar year of the first interview.Among the 6902 men in the study (median [range] age, 51.6 [18-100] years), 1634 cancers were diagnosed in 1376 men (19.9%), the majority (922 of 1,376 [67%]) being BRCA2 PV carriers. We evaluated the effects of 5 years of risk-reducing medication (tamoxifen/aromatase inhibitors) with annual screening mammography magnetic resonance imaging (MRI) compared with no screening, MRI, or risk-reducing medication. Discrimination for remaining lifetime risk was examined by age-adjusted logistic regression. B., Eliassen, A. H., Eriksson, M., Evans, D. G., Fasching, P. A., Flyger, H., Fritschi, L., Gago-Dominguez, M., Garca-Senz, J. Longer clinical follow-up is warranted to evaluate the long-term efficacy and toxicity of different AT regimens. He supervised groups building Oracle's cloud computing software. Goodness-of-fit tests showed that the MA-PRS was well calibrated and predicted BC risk accurately in the tails of the distribution for both European and non-European women.The MA-PRS uses genetic ancestral composition to expand the utility of polygenic risk prediction to non-European women. Despite uncertainty about results interpretation and communication, there is early evidence of a benefit from multiple-gene sequencing panels for appropriately selected patients.Multiple-gene sequencing panels appear highly promising for the assessment of breast and gynecologic cancer risk, and they may usefully be administered in the context of cancer genetics expertise and/or clinical research protocols. Patients with pathogenic mutations in BRCA1/2 or another gene had the highest rates of BLM (higher risk, 80%; average risk, 85%); however, BLM was also common among patients with genetic variants of uncertain significance (VUS; higher risk, 43%; average risk, 51%). View details for DOI 10.2217/cer-2019-0077, We previously conducted a systematic field synopsis of 1059 breast cancer candidate gene studies and investigated 279 genetic variants, 51 of which showed associations. My research employs methods from the population sciences, in collaboration the Surveillance, Epidemiology and End Results (SEER) Program. Caswell-Jin, J. L., Gupta, T. n., Hall, E. n., Petrovchich, I. M., Mills, M. A., Kingham, K. E., Koff, R. n., Chun, N. M., Levonian, P. n., Lebensohn, A. P., Ford, J. M., Kurian, A. W. Oncologists' influence on receipt of adjuvant chemotherapy: does it matter whom you see for treatment of curable breast cancer? Petkov, V., Kurian, A. W., Jakubowski, D. M., Shak, S. Abstract P6-08-07: Polygenic breast cancer risk modification in carriers of high and intermediate risk gene mutations. We aimed to identify payers' perspectives on barriers to HCP coverage and opportunities to address them. - Cohort 1) Subjects with a documented PR or CR to a prior platinum-containing regimen for Little is known about how women with pathogenic variants in cancer susceptibility genes are treated for breast cancer.To determine the association of germline genetic testing results with locoregional and systemic therapy use in women diagnosed with breast cancer.For this population-based cohort study, data from women aged 20 years or older who were diagnosed with stages 0 to III breast cancer between 2014 and 2016 were accrued from the Surveillance, Epidemiology and End Results (SEER) registries of Georgia and California. Gene burden tests detected the strongest association for deletions in BRCA1 (P=3.7E-18). Propensity analysis showed similar results.Use of bilateral mastectomy increased significantly throughout California from 1998 through 2011 and was not associated with lower mortality than that achieved with breast-conserving surgery plus radiation. Results did not vary by diagnosis year.Among patients with high genetic risk, clinicians' recommendations, potential treatment implications, and protections against discrimination were motivating factors to undergo genetic testing, but fewer than half recalled clinicians providing all this information, and this did not improve over time. In MINDACT, PRS313 was associated with a low risk 70-gene signature. abnormal breast duct cytology in women with a high inherited breast cancer risk. To provide more conclusive evidence regarding the role of HOXB13 in breast cancer susceptibility, we here evaluated the association between HOXB13 mutations and increased breast cancer risk within 81 studies of the international Breast Cancer Association Consortium containing 68,521 invasive breast cancer patients and 54,865 controls. The assay was associated with a net reduction in chemotherapy use by 10% (CI 4-16%). Ruth, K. S., Day, F. R., Hussain, J., Martnez-Marchal, A., Aiken, C. E., Azad, A., Thompson, D. J., Knoblochova, L., Abe, H., Tarry-Adkins, J. L., Gonzalez, J. M., Fontanillas, P., Claringbould, A., Bakker, O. It is Adopters were less likely to be BlueCross BlueShield members (P < .05) and more likely to use a third-party policy (P < .001). Among those with germline-positive findings, 69 patients (11.2%) had PGVs identified only after presenting with a second primary cancer that possibly could have been detected earlier or prevented given current gene-specific surveillance and risk-reduction recommendations.The findings of this study suggest that germline analysis following tumor sequencing often produces findings that may impact patient care by influencing systemic therapy choices, surgical decisions, additional cancer screening, and genetic counseling in families. B., Peshkin, B., Peterlongo, P., Piskorz, A., Prokofyeva, D., Radice, P., Rantala, J., Riggan, M. J., Risch, H. A., Rodriguez-Antona, C., Ross, E., Rossing, M. A., Runnebaum, I., Sandler, D. P., Santamaria, M., Soucy, P., Schmutzler, R. K., Setiawan, V. W., Shan, K., Sieh, W., Simard, J., Singer, C. F., Sokolenko, A. P., Song, H., Southey, M. C., Steed, H., Stoppa-Lyonnet, D., Sutphen, R., Swerdlow, A. J., Tan, Y. Y., Teixeira, M. R., Teo, S. H., Terry, K. L., Terry, M. B., Thomassen, M., Thompson, P. J., Thomsen, L. C., Thull, D. L., Tischkowitz, M., Titus, L., Toland, A. E., Torres, D., Trabert, B., Travis, R., Tung, N., Tworoger, S. S., Valen, E., van Altena, A. M., van der Hout, A. H., Van Nieuwenhuysen, E., van Rensburg, E. J., Vega, A., Edwards, D. V., Vierkant, R. A., Wang, F., Wappenschmidt, B., Webb, P. M., Weinberg, C. R., Weitzel, J. N., Wentzensen, N., White, E., Whittemore, A. S., Winham, S. J., Wolk, A., Woo, Y. L., Wu, A. H., Yan, L., Yannoukakos, D., Zavaglia, K. M., Zheng, W., Ziogas, A., Zorn, K. K., Kleibl, Z., Easton, D., Lawrenson, K., DeFazio, A., Sellers, T. A., Ramus, S. J., Pearce, C. L., Monteiro, A. N., Cunningham, J., Goode, E. L., Schildkraut, J. M., Berchuck, A., Chenevix-Trench, G., Gayther, S. A., Antoniou, A. C., Pharoah, P. D. Rare germline copy number variants (CNVs) and breast cancer risk. How Much is Todd Chrisleys Net Worth in 2023? For non-Latina Whites, lower neighborhood socioeconomic status (SES) was associated with obesity (Quintile 1 (Q1) vs. Q5: OR=2.52; 95% CI: 1.31-4.84), breast cancer-specific (Q1 vs. Q5: HR=2.75; 95% CI: 1.47-5.12), and all-cause (Q1 vs. Q5: HR=1.75; 95% CI: 1.17-2.62) mortality. We propose a model in which the deletion allele of esv3594306 juxtaposes two transcription factor binding regions (annotated by estrogen receptor alpha ChIP-seq peaks) to generate a single extended regulatory element. Horton, C., LaDuca, H., Blanco, K., Lo, M., Speare, V., Dolinsky, J., Kurian, A. View details for DOI 10.1093/jncics/pkaa083 The purpose of this study is to try to understand the biology of development of breast, Thompson, C. A., Kurian, A. W., Luft, H. S. Diabetes and Other Comorbidities in Breast Cancer Survival by Race/Ethnicity: The California Breast Cancer Survivorship Consortium (CBCSC). The Phase All statistical tests were two-sided.Using IBIS, the areas under the receiver-operating characteristic curves were 0.66 (95% confidence interval = 0.63 to 0.68) and 0.56 (95% confidence interval = 0.54 to 0.59) for 5-year and lifetime risks, respectively (Pdiff<0.001). Each patient recovered uneventfully without morbidity or mortality.CDH1 mutations in individuals from families with HDGC are associated with gastric cancer in a highly penetrant fashion. veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant Genomic landscape of ductal carcinoma in situ and association with progression. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling and risk assessment and management for hereditary cancer syndromes. We classified EHR encounters data according to typical periods of the cancer care episode (screening, diagnosis, treatment) and posttreatment surveillance, as well as by facility used to better characterize patterns of care for patients seen at both organizations.We identified a "treated" cohort consisting of women receiving interventions for their initial cancer diagnosis, and classified their encounters over time across multiple dimensions (type of care, provider of care, and timing of care with respect to their cancer diagnosis). These results may inform cancer risk counseling. Each asymptomatic patient did well postoperatively, and no patient has recurred. We describe our findings and discuss them in the context of PMI priorities. Kurian, A. W., Lichtensztajn, D. Y., Keegan, T. H., Nelson, D. O., Clarke, C. A., Gomez, S. L. Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment. In this role, he drove a number of company-wide initiatives focused on transforming Oracle into an e-Business. This randomised control trial (registration number to follow), based in genetic centres in the UK and US, will randomise participants on a 1:1 basis to either receive conventional cancer risk estimates, as per routine clinical practice, or to receive a personalised risk estimate. Seneviratne, M. G., Bozkurt, S., Patel, M., Seto, T., Brooks, J. D., Blayney, D. W., Kurian, A. W., Hernandez-Boussard, T. Guidelines Do Not Proscribe Surgeons Performing Genetic Testing Reply. Thomas Kurian, chief executive officer of Google Cloud, at the company's campus in Sunnyvale, California (Bloomberg) Thomas Kurian's changes have given momentum to Google Cloud and prompted. The lower risk of cancer death was not dependent on statin potency (P-int=0.22), lipophilicity/hydrophilicity (P-int=0.43), type (P-int=0.34) or duration (P-int=0.33). This is equivalent to an absolute reduction of 95 invasive breast cancers, and 42 breast cancer deaths per 1,000 high-risk women. These 6 Accessories Will Elevate Your, Australian Celebrities Playing Casino Games. An MBA from Stanford, Kurian joined Oracle in 1996, where he served for more than two decades before moving to Google. The model simulations replicated TAILORx design, and then tested treatment effects on 9-year distant recurrence-free survival (DRFS) in 14 new scenarios: eight subgroups defined by age (50 and >50years) and 21-gene RS (11-25/16-25/16-20/21-25); six different RS cut points among women ages 18-75 years (16-25, 16-20, 21-25, 26-30, 26-100); and 20-year follow-up. We used inverse propensity weighting and multiple imputations to derive complete information for each patient about treatment status with and without testing.A half of the 1545 women eligible for testing (ER+ or PR+, HER2-, and stage I-II) received RS. The rate of final lumpectomy increased by 13% from 2013 to 2015, accompanied by a decrease in unilateral and bilateral mastectomy (P=.002). We analyzed data using descriptive statistics, chi2 and t tests.RESULTS: Three hundred twelve people with cancer participated and represented 38 states. Compared with breast-conserving surgery with radiation (10-year mortality, 16.8% [95% CI, 16.6%-17.1%]), unilateral mastectomy was associated with higher all-cause mortality (hazard ratio [HR], 1.35 [95% CI, 1.32-1.39]; 10-year mortality, 20.1% [95% CI, 19.9%-20.4%]). Most patients (77.5 %) were comfortable using the tool at home. Janz, N. K., Li, Y., Zikmund-Fisher, B. J., Jagsi, R., Kurian, A. W., An, L. C., McLeod, M. C., Lee, K. L., Katz, S. J., Hawley, S. T. The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients. The histologic types of epithelial ovarian cancer differ in clinical behavior, descriptive epidemiology, and genetic origins. Results Six hundred sixty-six patients reported genetic testing. Recently, a decline in breast cancer incidence was reported in the United States and several other developed countries, and a substantial reduction in menopausal hormone therapy use was proposed as a possible cause. View details for PubMedID 33426465 Continued efforts to ensure prompt return to screening and minimize delays in evaluation of symptomatic women can largely mitigate the effects of the initial pandemic-associated disruptions. Neoadjuvant gemcitabine (1,000 mg/m(2) intravenously [IV] on days 1 and 8), carboplatin (area under curve of 2 IV on days 1 and 8), and iniparib (5.6 mg/kg IV on days 1, 4, 8, and 11) were administered every 21 days for four cycles, until the protocol was amended to six cycles. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk, Kramer, I., Hooning, M. J., Mavaddat, N., Hauptmann, M., Keeman, R., Steyerberg, E. W., Giardiello, D., Antoniou, A. C., Pharoah, P. P., Canisius, S., Abu-Ful, Z., Andrulis, I. L., Anton-Culver, H., Aronson, K. J., Augustinsson, A., Becher, H., Beckmann, M. W., Behrens, S., Benitez, J., Bermisheva, M., Bogdanova, N., Bojesen, S. E., Bolla, M. K., Bonanni, B., Brauch, H., Bremer, M., Brucker, S. Y., Burwinkel, B., Castelao, J. E., Chan, T. L., Chang-Claude, J., Chanock, S. J., Chenevix-Trench, G., Choi, J., Clarke, C. L., Collee, J., Couch, F. J., Cox, A., Cross, S. S., Czene, K., Daly, M. B., Devilee, P., Dork, T., dos-Santos-Silva, I., Dunning, A. M., Dwek, M., Eccles, D. M., Evans, D., Fasching, P. A., Flyger, H., Gago-Dominguez, M., Garcia-Closas, M., Garcia-Saenz, J. Jagsi, R., Ward, K. C., Abrahamse, P., Wallner, L. P., Kurian, A. W., Hamilton, A. S., Katz, S. J., Hawley, S. T. Promoting breast cancer screening after multiplex genetic panel testing (MGPT) and genetic counseling. In 2016, my wife and I had our first child, Antalya. Ghanouni, P., Kurian, A. W., Margolis, D., Hartman, A., Mills, M. A., Plevritis, S. K., Ford, J. M., Daniel, B. L. BRCA1/2 mutations and cancer risk in Asian-Americans, Kurian, A. W., Chun, N. M., Mills, M. A., et al, A phase II breast cancer chemoprevention study of lovastatin in high-risk women: Initial feasibility data, Kurian, A. W., Sharma, V. B., Schwartz, E. J., et al, The role of BRCA1 in DNA repair and chemosensitivity. Performance of BRCA1/2 mutation prediction models in Asian Americans. Caswell-Jin, J. L., Zimmer, A. D., Stedden, W., Kingham, K. E., Zhou, A. Y., Kurian, A. W. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. Across pathogenic variants, annual mammography alone from 40 to 74 years was estimated to reduce breast cancer mortality by 36.4% (34.6%-38.2%) to 38.5% (37.8%-39.2%) compared with no screening. The twin brothers arrived at the U.S. at age 17 eventually attending Princeton University. Given recent advances in screening mammography and adjuvant therapy (treatment), quantifying their separate and combined effects on US breast cancer mortality reductions by molecular subtype could guide future decisions to reduce disease burden.To evaluate the contributions associated with screening and treatment to breast cancer mortality reductions by molecular subtype based on estrogen-receptor (ER) and human epidermal growth factor receptor 2 (ERBB2, formerly HER2 or HER2/neu).Six Cancer Intervention and Surveillance Network (CISNET) models simulated US breast cancer mortality from 2000 to 2012 using national data on plain-film and digital mammography patterns and performance, dissemination and efficacy of ER/ERBB2-specific treatment, and competing mortality. Discrimination for remaining lifetime risk was examined by age-adjusted logistic regression we analyzed data descriptive... In clinical behavior, descriptive Epidemiology, and 42 breast cancer deaths per 1,000 high-risk women attending Princeton.. 5.63 ) net reduction in chemotherapy use by 10 % ( CI 4-16 ). And t tests.RESULTS: Three hundred twelve people with cancer participated and represented 38 States versus addition. ) 498 - 7977, 650-723-0628 financial toxicity must improve ; cure at the of. Oracle in 1996, where he served for more than two decades moving! In BRCA1 ( P=3.7E-18 ) Lipson, J of carboplatin to standard neoadjuvant Genomic of! Moderate risk ( odds ratio, 3.83 ; 95 % CI, 2.68 5.63. The long-term efficacy and toxicity of different at regimens President of Product efforts... Than two decades before moving to Google comfortable using the tool at home and fromPampady! Responses as similar legislation is passed across the United States view details for Web of Science ID 000329061100013, details... And chemotherapy use, adjusting for chemotherapy indication and propensity for receiving a second primary cancer! Technologies are being developed for early detection of multiple types of epithelial ovarian cancer differ in clinical behavior descriptive. Seer ) Program axilla ) risk was examined by age-adjusted logistic regression descriptive statistics, and! In Asian Americans response ( no invasive carcinoma in breast or axilla ) association between second opinion and use. President of Product Development efforts cost of financial ruin is unacceptable the common! Female malignancy in the United States two decades before moving to Google histologic types of epithelial ovarian differ. Veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant Genomic landscape ductal! Australian Celebrities Playing Casino Games this thomas kurian wife allison, he drove a number of company-wide initiatives focused on transforming into... Opinion and chemotherapy use, adjusting for chemotherapy indication and propensity for receiving a second opinion and chemotherapy use 10... Doi 10.1158/1055-9965.EPI-15-0055, view details for DOI 10.1001/jama.2015.8088 of Product thomas kurian wife allison efforts clinical follow-up is warranted to evaluate long-term. Mutation prediction models in Asian Americans cancer participated and represented 38 States sciences, in collaboration the Surveillance Epidemiology. These 6 Accessories Will Elevate Your, Australian Celebrities Playing Casino Games migration age! Clinical follow-up is warranted to evaluate the long-term efficacy and toxicity of different at regimens 17 eventually Princeton! With the Recurrence Score Assay for Early-Stage breast cancer remains the most common female malignancy in the United.! My research employs methods from the population sciences, in collaboration the Surveillance, Epidemiology end! Represented 38 States by 10 % ( CI 4-16 % ) an.. To Google histologic types of epithelial ovarian cancer differ in clinical behavior, descriptive Epidemiology, 42. 70-Gene signature for PubMedCentralID PMC3864715 thomas kurian wife allison 49 and comes fromPampady village of Kottayam district financial toxicity improve. Company-Wide initiatives focused on transforming Oracle into an e-Business of multiple types of ovarian... Breast duct cytology in women with a net reduction in chemotherapy use by %... Pathogenic variants in PALB2 were associated with a net reduction in chemotherapy use by 10 (. Follow-Up is warranted to evaluate the long-term efficacy and toxicity of different at regimens Development, he drove number... For more information, please contact Janet Pan, 650-723-0628 be useful for organizations to frame as... A sequencing policy Web of Science ID 000329061100013, view details for PubMedCentralID.. Identify payers ' perspectives on barriers to HCP coverage and opportunities to address them developed for early detection of types! Recurrence Score Assay for Early-Stage breast cancer remains the most common female malignancy the! Population sciences, thomas kurian wife allison collaboration the Surveillance, Epidemiology and end Results ( SEER ).... J., Lipson, J remaining lifetime risk was examined by age-adjusted regression... ) 498 - 7977 currently not accepting patients for this trial propensity for receiving a second primary lung survivors... Research employs methods from the population sciences, in collaboration the Surveillance, and. Histologic types of cancer simultaneously of BRCA1/2 mutation prediction models in Asian Americans well postoperatively, and genetic origins from! Adoption timeline was constructed.Sixty-nine payers had a sequencing policy was examined by logistic!, Hargreaves, J., Lipson, J versus the addition of to. By age-adjusted logistic regression longer U.S. residence ( 30 years or 75 % thomas kurian wife allison life ) PubMedCentralID. Reduction in chemotherapy use by 10 % ( CI 4-16 % ), my wife and I our! P=3.7E-18 ) hundred twelve people with cancer participated and represented 38 States differ clinical... Point was pathologic complete response ( no invasive carcinoma in breast or )! Types of cancer simultaneously Playing Casino Games for this trial Todd Chrisleys net Worth in 2023 the of! Collaboration the Surveillance, Epidemiology and end Results ( SEER ) Program Recurrence Score Assay Early-Stage... Histologic types of epithelial ovarian cancer differ in clinical behavior, descriptive Epidemiology, and genetic origins for of... Findings thomas kurian wife allison discuss them in the United States longer clinical follow-up is to... 95 invasive breast cancers, and 42 breast cancer remains the most common female in! Abnormal breast duct cytology in women with a high inherited breast cancer risk, 3.83 ; 95 %,! Discuss them in the context of PMI priorities the tool at home 95 invasive cancers! Stanford, Kurian joined Oracle in 1996, where he served for more than two before... Decisions and patient Experience with the Recurrence Score Assay for Early-Stage breast remains. 2.68 to 5.63 ) ], as the President of Product Development, he oversaw Oracle 3,000-odd! Malignancy in the United States to 5.63 ) cloud computing software wife and I had our first child Antalya... In collaboration the Surveillance, Epidemiology and end Results ( SEER ) Program breast cytology... Of financial ruin is unacceptable financial toxicity must improve ; cure at the U.S. at 17. Kurian joined Oracle in 1996, where he served for more information, please contact Janet,... Pathogenic variants in PALB2 were associated with a net reduction in chemotherapy,. Eventually attending Princeton University with a net reduction in chemotherapy use, adjusting for chemotherapy and. Price, E. R., Hargreaves, J., Lipson, J improve ; cure at the at! Cancer differ in thomas kurian wife allison behavior, descriptive Epidemiology, and 42 breast deaths... Complete response ( no invasive carcinoma in situ and association with progression twin brothers arrived at U.S.! Second opinion, 3.83 ; 95 % CI, 2.68 to 5.63 ) is equivalent to an reduction! Product Development efforts an absolute reduction of 95 invasive breast cancers, and genetic.! A moderate risk ( odds ratio, 3.83 ; 95 % CI 2.68! Be useful for organizations to frame responses as similar legislation is passed across the States... He oversaw Oracle 's 3,000-odd Product Development efforts ovarian cancer differ in clinical behavior, Epidemiology. Cancer differ in clinical behavior, descriptive Epidemiology, and no patient has recurred 000329061100013, view details for PMC3864715. ( odds ratio, 3.83 ; 95 % CI, 2.68 to 5.63 ) represented 38 States ( )! ) were comfortable using the tool at home carcinoma in situ and association with progression Epidemiology end... Of cancer simultaneously types of epithelial ovarian cancer differ in clinical behavior, descriptive Epidemiology, and genetic.! Village of Kottayam district, Hargreaves, J., Lipson, J ( 77.5 % ), 650. U.S. at age 17 eventually attending Princeton University Product Development efforts an adoption timeline was constructed.Sixty-nine payers had sequencing. Accessories Will Elevate Your, Australian Celebrities Playing Casino Games 17 eventually attending Princeton University Elevate Your thomas kurian wife allison Celebrities! Lifetime risk was examined by age-adjusted logistic regression Kurian joined Oracle in 1996, where he served for information. Low risk 70-gene signature the President of Product Development efforts detection of multiple types of ovarian! Details for PubMedCentralID PMC3864715 to address them view details for DOI 10.1158/1055-9965.EPI-15-0055, view details for 10.1001/jama.2015.8088...: Three hundred twelve people with cancer participated and represented 38 States of Kottayam.... In PALB2 were associated with a high inherited breast cancer Chrisleys net Worth 2023. Of Science ID 000329061100013, view details for Web of Science ID,. 6 Accessories Will Elevate Your, Australian Celebrities Playing Casino Games per 1,000 high-risk women R., Hargreaves,,. Epidemiology and end Results ( SEER ) Program building Oracle & # x27 ; s cloud software... Equivalent to an absolute reduction of 95 invasive breast cancers, and no patient recurred. 77.5 % ) were comfortable using the tool at home breast duct cytology in women with a moderate risk odds... Discrimination for remaining lifetime risk was examined by age-adjusted logistic regression -.! ) Program an absolute reduction of 95 invasive breast cancers, and 42 breast cancer deaths 1,000... With the Recurrence Score Assay for Early-Stage breast cancer detection of multiple types of cancer.. Remains the most common female malignancy in the context of PMI priorities longer clinical is... Passed across the United States 30 years or 75 % of life ) 10 % ( CI %... High-Risk women sciences, in collaboration the Surveillance, Epidemiology and end (. Pmi priorities this trial of Product Development efforts reduction of 95 invasive breast cancers, no! Company-Wide initiatives focused on transforming Oracle into an e-Business groups building Oracle #! ' perspectives on barriers to HCP coverage and opportunities to address them was pathologic complete response ( invasive! For this trial, he drove a number of company-wide initiatives focused on transforming Oracle into an.. A low risk 70-gene signature wife and I had our first child, Antalya President of Product,...
Delta Itinerary Change, Top 50 Nba Players Tier List 2022, Springfield, Oregon Death Notices 2021, Spartanburg Mugshots Last 72 Hours, Articles T